AGC Biologics
1 / 2
Viral Vectors
Backbone of Innovation: How CDMO Vector Platforms Are Accelerating Gene Therapy Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-25-NI-09Jul 21, 2025
Formulation
Formulation and Analytics Platforms Transforming Drug Product Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-25-NI-06Jul 16, 2025
AGC Biologics
AGC Biologics Completes pDNA and mRNA Expansion at Heidelberg location
AGC Biologics
PR-M10-23-02Oct 12, 2023
AGC Biologics
Cell Therapy Manufacturing
RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies
AGC Biologics
PR-M08-22-03Aug 16, 2022
Unmet Needs
In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
Pharma's Almanac
PAO-06-022--RT-01Jun 24, 2022
Industry Challenges
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
Pharma's Almanac
O-06-022--RT-01Jun 24, 2022
AGC Biologics
New Facility
AGC Biologics Invests in Viral Vector Suspension at New U.S. Campus
AGC Biologics
PR-M05-22-13-359May 18, 2022
Leadership
Q: What’s the key to being a leader in the industry?
Pharma's Almanac
PAO-03-022-RT-02Mar 11, 2022
Milestones
Q: What important company milestone do you anticipate reaching in 2022?
Pharma's Almanac
PAO-03-022-RT-01Mar 11, 2022
AGC Biologics
COVID-19 Vaccine
AGC Biologics Supports Omicron-Based Vaccine Candidate Manufacturing with Starting Material
AGC Biologics
PR-M02-22-07Feb 09, 2022
Personalized and Precision Medicine
Q: What do you see as the key innovations or technologies that will make personalized/precision medicine a reality?
Pharma's Almanac
PAO-12-21-RT-01Jan 07, 2022
Therapeutic Progress
Q: For what therapeutic area do you think we will see the greatest progress in the coming years?
Pharma's Almanac
PAO-12-21-RT-02Jan 07, 2022
AGC Biologics
Expansion
AGC Biologics Expands pDNA and mRNA Manufacturing Capacity at Heidelberg Facility
AGC Biologics
PR-M09-21-04Sep 14, 2021
AGC Biologics
Partnership
Novavax Selects AGC Biologics to Manufacture Matrix-M Adjuvant for Novel COVID-19 Vaccine
AGC Biologics
PR-M06-20-NI-008Jun 05, 2020
AGC Biologics
Expansion
AGC Biologics Expands Plasmid DNA Offering
AGC Biologics
PR-M12-19-NI-030Dec 20, 2019
Antibody-Drug Conjugate
Fast-Tracking ADC Development and Commercialization
Matteo Piazza
PROVEO
PAP-Q4-19-CL-003Dec 06, 2019
Customer Centricity
Uniting Innovation and Customer-Centricity
Patricio E. Massera
AGC Biologics
PTV-M08-19-BIO-001Aug 12, 2019
Customer Focus
Designing a Customer-Centric CDMO
Patricio E. Massera
AGC Biologics
PAP-Q2-2019-CL-003May 24, 2019
AGC Biologics
Appointment
Dr. Gustavo Mahler Resigns as Chief Executive Officer of AGC Biologics, Patricio Massera to Succeed as CEO Effective May 1st, 2019
AGC Biologics
PR-M04-19-NI-032Apr 04, 2019
AGC Biologics
Biologics Manufacturing
AGC Triples U.S. Biopharmaceutical Production Capacity
AGC Biologics
PR-M12-18-NI-066Dec 18, 2018
1 / 2